Olema Oncology, a San Francisco-based biopharmaceutical company focused on developing targeted therapies for hormone receptor-positive breast cancer, has signed a lease for 38,176 square feet at 365 Oyster Point Blvd. in South San Francisco. The seven-year lease begins in September and will give the clinical-stage drug developer additional space for research-and-development operations as it advances its oncology pipeline.
Olema Oncology inks lease at South San Francisco life sciences campus
Phase II building at Kilroy Oyster Point development secures long-term tenant
RELATED ARTICLES
This news story is available exclusively to CoStar subscribers.
Watch the video to learn how you can access industry leading CRE news and the data analytics you need to drive success.
This news story is available exclusively to CoStar subscribers.
Ready to Learn More?
Sign Up For a Personalized Demo.
Sign Up For a Demo To Learn More.
Already A Subscriber? Sign In
IN THIS ARTICLE
- Properties
- Phase II - Building F
365 Oyster Point Blvd, South San Francisco, CA
- Companies
- Kilroy Realty Corporation
Real Estate
- Contacts
- Scott Miller
Executive Managing Director, JLL
- Mark Bodie
Senior Managing Director, JLL
- Toss Vallentine
Senior Managing Director, JLL